This week, U.S. drugmaker Novavax said it’s ready to start a new midstage trial of its experimental COVID-19 vaccine in South Africa. The Maryland company has said it’s on track to begin final-stage trials as soon as late September.
Last month, the Trump administration awarded Novavax a $1.6 billion contract as part of its Operation Warp Speed program, which aims to deliver 300 million doses of a vaccine against the coronavirus by January.
Here & Now‘s Tonya Mosley speaks with Dr. Gregory Glenn, president of research and development at Novavax and head of the company’s vaccines programs.
This article was originally published on WBUR.org.
Copyright 2020 NPR. To see more, visit https://www.npr.org. 9(MDA5MTc0MDI0MDEzMzE4MjI4ODdlOTk4MA004))